The rise of GLP-1s has made treat­ing obe­si­ty one of the largest mar­ket op­por­tu­ni­ties in his­to­ry. It al­so has re­in­forced a detri­men­tal re­la­tion­ship be­tween ...

New data suggest Restylane Lyft or Contour in combination with Sculptra corrects contour deficiencies in patients experiencing facial volume loss following medication-driven weight loss ...

The latter has made little difference: the popularity of Ozempic and other GLP-1 receptor agonists ... due to a surge in “off-label” prescriptions for weight loss. An “Ozempic crackdown ...

With obesity rates tripling over the past 60 years, GLP-1 medications dominated the conversation in 2024 as an effective solution for this pervasive issue. But are they a one-shot deal?

People lose weight via three primary methods: diet and exercise, weight loss surgery and GLP-1 weight loss drugs. The suggested method is based on the amount of weight a person wants or needs to ...

Market News Alerts Updates that DarioHealth Corp. (Nasdaq: DRIO) is taking another bold step into the rapidly growing weight-loss market, now projected to exceed $100 billion annually by 2030. The ...

morgantown, w.va. – Millions of obese Americans have achieved successful weight loss through use of glucagon-like peptide-1 agonists (GLP-1), a game-changing class of obesity medications.

NEW YORK--(BUSINESS WIRE)--Market News Alerts Updates that DarioHealth Corp. (Nasdaq: DRIO) is taking another bold step into the rapidly growing weight-loss market, now projected to exceed $100 ...